Filtered By:
Drug: Dexamethasone

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 7130 results found since Jan 2013.

Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study
Conclusions This study demonstrates that the prophylactic administration of dexamethasone before chemoembolization is an effective way to reduce PES.
Source: Journal of Vascular and Interventional Radiology - September 21, 2017 Category: Radiology Source Type: research

GSE110886 Comparison of Gene Expression between stromal vascular cells (SVC) and newly identified adipose precursor (SPA)
Contributors : Koichiro Taguchi ; Kazuo KajitaSeries Type : Expression profiling by arrayOrganism : Mus musculusWe have identified proliferative cells in adipose tissue expressing adipocyte specific genes, which were named small proliferative adipocytes (SPA). Comparison of gene expression by microarray and real time PCR among stromal vascular cells (SVC), SPA and mature adipocyte (MA) revealed that adipocyte specific genes and several neuronal genes were increased in the order of SVC
Source: GEO: Gene Expression Omnibus - February 21, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research

A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema
This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).
Source: BMC Ophthalmology - May 21, 2018 Category: Opthalmology Authors: Ye He, Xin-jun Ren, Bo-jie Hu, Wai-Ching Lam and Xiao-rong Li Tags: Research article Source Type: research

Cancers, Vol. 10, Pages 492: Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
nin To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18–20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III trials and should result in revision of the landmark Stupp trial as a historical control for ...
Source: Cancers - December 5, 2018 Category: Cancer & Oncology Authors: Aleksei A. Stepanenko Vladimir P. Chekhonin Tags: Review Source Type: research

Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury
Publication date: Available online 28 February 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Xing Zhou, Yanjiao Wu, Lifeng Ye, Yunting Wang, Kaiming Zhang, Lingjun Wang, Yi Huang, Lei Wang, Shaoxiang Xian, Yang Zhang, Yang ChenAbstractThe loss of endothelial connective integrity and endothelial barrier dysfunction can lead to increased vascular injury, which is related to the activation of endothelial inflammasomes. There are evidences that low concentrations of aspirin can effectively prevent cardiovascular diseases. We hypothesized that low-dose aspirin could ameliorate endothelial injury by inhibiting the activation...
Source: Acta Pharmaceutica Sinica B - March 1, 2019 Category: Cancer & Oncology Source Type: research

Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion & #8211;related macular edema: A systematic review and meta-analysis of randomized controlled trials
Qiuming Hu, Haoyu Li, Wenhua Xu, Yi Du, Chao Ma, Jianfeng HeIndian Journal of Ophthalmology 2019 67(11):1800-1809 This systematic review aimed to evaluate the effectiveness and safety of intravitreal dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatments for macular edema (ME) secondary to retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), and branch retinal vein occlusion (BRVO). The electronic databases comprehensively searched for the studies that compared DEX with anti-VEGF treatments in patients suffering from RVO-related ME. The effectiveness was esti...
Source: Indian Journal of Ophthalmology - October 21, 2019 Category: Opthalmology Authors: Qiuming Hu Haoyu Li Wenhua Xu Yi Du Chao Ma Jianfeng He Source Type: research

In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes.
In this study, we examined whether the salutary effects of exercise are associated with an enhanced metabolic profile. Analysis of the NAD and ATP content in the tibialis anterior muscle of trained and non-trained animals indicated that exercise increases both NAD and ATP; however, Dex treatment had no effect on any of the experimental groups. Likewise, Dex did not change NAD and ATP in cultured endothelial cells following 24 h and 48 h of incubation with high concentrations. Reduced VEGF-stimulated NO production, however, was verified in endothelial cultured cells. Reduced NO was not associated with changes in surviva...
Source: Free Radical Biology and Medicine - January 20, 2020 Category: Biology Authors: Herrera NA, Duchatsch F, Kahlke A, Amaral SL, Vasquez-Vivar J Tags: Free Radic Biol Med Source Type: research

Effect of dexamethasone intravitreal implant on visual acuity and foveal photoreceptor integrity in macular edema secondary to retinal vascular disease
Purpose: To evaluate the effect of the dexamethasone intravitreal (DEX) implant on the external limiting membrane (ELM) and ellipsoid zone (EZ) integrity in treatment na ïve patients with macular edema (ME) secondary to retinal vascular disease (RVD). Methods: Retrospective study conducted on patients with ME secondary to RVD, who underwent a DEX implant. Results: One-hundred eyes were included. Mean age was 70.3±11.1 years. Mean ELM integrity significantly improv ed from 1575.9±285.9 μm at baseline to 1711.7±244.0 μm at month 3, p
Source: Ophthalmologica - October 11, 2020 Category: Opthalmology Source Type: research

PSS5 The Cost-Effectiveness of Dexamethasone Intravitreal Implant Versus Anti-Vascular Endothelial Growth Factor Therapies for Eyes with a Phakic Lens in UK Clinical Practice
In 2015 the National Institute for Health and Care Excellence (NICE) recommended dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular oedema (DMO) where non-corticosteroid therapy is unsuitable or insufficiently responsive in pseudophakic eyes (TA349). However, DEX was not considered cost effective compared with ‘watch and wait’ (w&w) in phakic eyes. In 2019, NICE acknowledged that anti-vascular endothelial growth factors (anti-VEGFs) and laser treatments are frequently administered to insufficient responders given a lack of recommended alternatives (TA613).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. Lebbink, P. Morgan, F. Tefos, C. Lowry Source Type: research

Levosulpiride Relieved Persistent Hiccups in a Patient With COVID-19 and Vascular Cognitive Impairment
Conclusions Oral levosulpiride is a suitable option in persistent hiccups that occur in patients with COVID-19 pneumonia. To our knowledge, this is the fourth published case of persistent hiccups as a clinical feature of COVID-19.
Source: Clinical Neuropharmacology - September 1, 2021 Category: Neurology Tags: Case Reports Source Type: research

Acute Mountain Sickness Following Incremental Trekking to High Altitude: Correlation With Plasma Vascular Endothelial Growth Factor Levels and the Possible Effects of Dexamethasone and Acclimatization Following Re-exposure
Conclusion: First ascent findings suggest a hallmark of AMS could be elevated VEGF levels. The lack of an exercise-induced VEGF level change strengthened the notion that elevated plasma VEGF was brain-derived, and related to AMS.
Source: Frontiers in Physiology - October 21, 2021 Category: Physiology Source Type: research

Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic macular oedema: a systematic review with meta-analysis
Eye, Published online: 18 November 2021; doi:10.1038/s41433-021-01847-wIntravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic macular oedema: a systematic review with meta-analysis
Source: Eye - November 18, 2021 Category: Opthalmology Authors: Matteo Fallico Andrew Lotery Andrea Maugeri Giuliana Favara Martina Barchitta Antonella Agodi Andrea Russo Antonio Longo Vincenza Bonfiglio Teresio Avitabile Paola Marolo Enrico Borrelli Guglielmo Parisi Gilda Cennamo Claudio Furino Michele Reibaldi Source Type: research

Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment
ConclusionThe study showed that IDI caused a significant decrease in the FAZ area without any change in VD in patients with DME resistant to the anti-VEGF agents. IDI might be related to a decrease in the macular ischemia secondary to diabetic retinopathy.
Source: International Ophthalmology - June 23, 2022 Category: Opthalmology Source Type: research

Results of intravitreal dexamethasone implant (Ozurdex®) for retinal vascular diseases with macular edema: An observational study of real-life situations
To evaluate the efficacy of intravitreal dexamethasone implants (Ozurdex®) for the treatment of macular edema (ME) associated with retinal vascular diseases in real-life situations.
Source: Medicine - July 8, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Dexamethasone reduces vascular endothelial growth factor in comparison to placebo in post-operative chronic subdural hematoma samples: A target for future drug therapy?
ConclusionIt is evident that VEGF plays a critical role in the inflammatory response in CSDH. The post-operative reduction with dexamethasone could signal the mechanism by which it reduces recurrence. Novel therapies with a better side-effect profile than dexamethasone should be targeted at VEGF or potential alternatives such as IL-10 supplementation.
Source: Frontiers in Neurology - September 8, 2022 Category: Neurology Source Type: research